ORPHA:2349
Muscular pseudohypertrophy-hypothyroidism syndrome
Also known as: Hoffmann syndrome · Kocher-Debré-Semelaigne syndrome
Publications
134
45.9th percentile
Trials
0
Interventional, condition-specific
Researchers
636
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Muscular pseudohypertrophy - hypothyroidism, also known as Kocher-Debre-Semelaigne syndrome is a rare disorder characterized by pseudohypertrophy of muscles due to longstanding hypothyroidism.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016521
- UMLS:C0270958
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
134 matched papers (43 in last 10 years) Source
- Phenotype characterisedPresent
15 HPO annotations (e.g. Hypothyroidism; Jaundice; Gait disturbance) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
15
Associated phenotypes · MONDO:0016521
- Hypothyroidism
- Jaundice
- Gait disturbance
- Umbilical hernia
- Macroglossia
Showing 5 of 15 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
134
134 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
134 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
43 in the last 10 years · high confidence · 45.9th percentile (publications denominator)
Phrase hits: 134 · MeSH hits: 0
Who's working on it?
636
Distinct author names in 134 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bai KI2 papers · 1977Papers in Europe PMC
- 02Benvenga S2 papers · 2020
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Papers in Europe PMC - 03Cutler EA2 papers · 1978Papers in Europe PMC
- 04Darbà J2 papers · 2020
Department of Economics, Universitat de Barcelona, Barcelona, Spain darba@ub.edu.
Papers in Europe PMC - 05Gutch M2 papers · 2017
Department of Medicine, King George's Medical College, Lucknow, Uttar Pradesh, India.
Papers in Europe PMC - 06Haendel MA2 papers · 2026
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, United States.
Papers in Europe PMC - 07Kim SH2 papers · 2015
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Papers in Europe PMC - 08Kumar S2 papers · 2017
Department of Radiodiagnosis, King George's Medical College, Lucknow, Uttar Pradesh, India.
Papers in Europe PMC - 09Lee NC2 papers · 2025
Department of Medical Genetics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Papers in Europe PMC - 10Najjar SS2 papers · 1974Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- isrctn·ISRCTN10221007·No longer recruiting·A study to compare how the body takes in and gets rid of sefaxersen when given by an injection device or a regular syringe in healthy adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN85572126·No longer recruiting·A study to evaluate the safety and processing of RO7434656 by the body and the effects it has in healthy Chinese participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN23183841·No longer recruiting·A study to compare two different formulations of fenebrutinib and to assess the effect of food and rabeprazole on the processing of fenebrutinib by the body in healthy participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11899726·No longer recruiting·A study to evaluate how inavolisib is processed in the body of participants with moderate and highly reduced kidney function
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10681798·No longer recruiting·A study to investigate the safety, tolerability, disposition in the body, effects of RO7308480 on the body, and its changes in midazolam disposition in the body following oral administration in healthy participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73873157·No longer recruiting·A clinical trial to compare the safety and effectiveness of selnoflast with a placebo and understand how the body processes selnoflast in people with moderate to severe asthma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN50261938·Suspended·Study to evaluate treatment efficacy by monitoring minimal residual disease in an early breast cancer population
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN39200026·No longer recruiting·A study to evaluate the effects of various degrees of reduced kidney function on how the study drug (RO7223280) is broken down and eliminated from the body
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN68010602·No longer recruiting·Exploring the link between bipolar disorder and medical diseases: an investigation of risk factors and biological characteristics for better prevention and treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14442671·No longer recruiting·A study to evaluate the drug-drug interaction potential of pralsetinib in combination with substrates of various transporters or CYP enzymes or a combined oral contraceptive in participants with advanced or metastatic solid tumors that are not responsive to standard therapies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN75434529·No longer recruiting·A study to evaluate the effects of RO7269162 on the body following oral administration in presymptomatic gene mutation carriers and non-carriers from the same kindred in Alzheimer’s Disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15842444·Recruiting·Assessing the safety of atezolizumab being directly administered to the bladder in bladder cancer patients undergoing radical cystectomy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN27200385·No longer recruiting·A study to assess the safety and distribution of GDC-8264 in combination with standard of care corticosteroid treatment in the blood of participants with high-risk acute graft-versus-host disease (aGVHD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14383396·No longer recruiting·A study to investigate the effect of various degrees of liver damage on the processing by the body of a single dose of RO7223280 given through the vein
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10010669·No longer recruiting·A study to assess the effect of tiragolumab in presence of atezolizumab and bevacizumab in participants detected with lung cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14030004·No longer recruiting·A study to evaluate the processing by the body of giredestrant in female participants of non-childbearing potential with impaired liver functions
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15639880·No longer recruiting·Study to evaluate the operational suitability of two point-of-care assay devices in a clinical setting
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12839469·No longer recruiting·A study to characterize the impact of dietary modification on inavolisib associated hyperglycaemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in participants with incurable metastatic solid tumours previously treated with multiple (≥2) lines of therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17780768·No longer recruiting·A study in healthy volunteers to investigate how different recipes and the particle size of an ingredient in the test medicine affects how the test medicine behaves
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57815030·No longer recruiting·A study to assess the distribution of entrectinib capsule in the blood of healthy adults compared to nasogastric and oral suspension of entrectinib
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14514128·No longer recruiting·A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab as an adjunct treatment in the prevention of vaso-occlusive episodes in sickle cell disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37043682·No longer recruiting·A study in healthy males to assess how the radiolabelled test medicine RO7223280 is broken down, processed and removed from the body
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89975936·No longer recruiting·A study evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy of crovalimab for the management of acute uncomplicated vaso-occlusive episodes in participants with sickle cell disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10520571·No longer recruiting·A study to assess the safety, processing by the body, and effects on the body following 4 weeks of selnoflast dosing in participants with coronary artery disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59409907·No longer recruiting·A study to compare how the body processes first and second generation RO7490677 (recombinant human pentraxin-2; rhPTX-2) drug products in healthy participants
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Muscular pseudohypertrophy-hypothyroidism syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Muscular pseudohypertrophy-hypothyroidism syndrome" OR "Hoffmann syndrome" OR "Kocher-Debré-Semelaigne syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Muscular pseudohypertrophy-hypothyroidism syndrome" OR "Hoffmann syndrome" OR "Kocher-Debré-Semelaigne syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T19:56:00.850Z
